ENvue Medical, Inc. (FEED) is a Healthcare stock trading at $0.42 (as of 2026-07-16), with a market capitalization of $4.71M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
NanoVibronix, Inc. develops noninvasive devices intended to activate biological responses, including UroShield and PainShield. The company operates in the United States, Europe, Australia, India, Israel, and other regions.
ENvue Medical develops noninvasive biological response-activating medical device products, including UroShield and PainShield, and operates across multiple geographic markets.
With gross margin of -8.4% and operating margin of -568.3% in the latest reported period, the profit model depends on whether ENvue can commercialize its device products at economics strong enough to cover operating costs.
Business quality (Weak): Clear product focus (UroShield, PainShield) and a defined device approach, but the latest reported margins show losses at both gross and operating levels, and there is no provided segment revenue or operating KPI to gauge underlying drivers.
| Price | $0.42 |
| Market Cap | $4.71M |
| Price / Book | 0.15 |
| Price / Sales | 2.44 |
| FCF Yield | -249.6% |
| Revenue (TTM) | $2.55M |
| Net Margin | -712.3% |
| Revenue Growth (YoY) | -51.6% |
| EPS Growth (YoY) | 92.2% |
| FCF Growth (YoY) | -19.8% |
| Altman Z-Score | -4.71 (distress) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | GEODE CAPITAL MANAGEMENT, LLC ($53352.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Doron Robert Besser |
| Employees | 31 |
| Country | US |
| IPO Date | 2025-12-12 |
Data as of 2026-07-16.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.